Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Resected NSCLC With Detectable ctDNA
NCT04625699Phase 2Withdrawn
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC). Primary endpoint: Number of evaluable patients enrolled at 36 months. Planned start Dec 2022; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04625699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625699.